CK Regeon Inc.

CK Regeon (CKR) provides innovative approaches to develop novel small molecules which can treat medically unmet needs diseases that are attributed to their pathogenic complexities. Our main platform technology is identifying key factors involving the multiple pathogeneses of target diseases and developing drugs improving overall pathological phenotypes with high efficacies by targeting the factor. CXXC5, a negative regulator of the Wnt/b-catenin pathway, functions via binding at an upstream component Dishevelled, it control whole Wnt/b-catenin pathway involving damaged tissue regeneration. The Wnt pathway is suppressed with overexpression of CXXC5 in the target diseases. Restoration of the Wnt signaling in the patient tissue by our compound inhibiting CXXC5-Dishevelled interaction results in highly effective therapeutic effects. The targeting diseases include obesity, diabetes, NASH, and Alzheimer’s for oral administration and hair loss and diabetic foot ulcer for topical application.